|
Aug 13
|
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
|
|
Aug 12
|
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
|
|
Jun 18
|
Ascletis Announces First Participants Dosed in U.S. Phase I Clinical Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor for the Treatment of Psoriasis
|
|
Jan 2
|
Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
|
|
Dec 5
|
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
|
|
Nov 13
|
Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB
|
|
Nov 9
|
Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023
|
|
Sep 5
|
Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
|
|
Jul 20
|
Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
|